TapImmune Inc. (TPIV) Announces the Appointment of Sherry Grisewood to the Board of Directors
3/20/2013 9:21:21 AM
More...
|
TapImmune Inc. (TPIV) to Present at the Florida Road Show Conference on March 14, 2013
3/13/2013 8:48:48 AM
More...
|
Details of HER-2/Neu Class I Antigen Licensed by TapImmune Inc. (TPIV) Published in Journal of Immunology: Antigen is a Naturally Processed Epitope for Breast Cancer Vaccines
1/22/2013 10:19:55 AM
More...
|
TapImmune Inc. (TPIV) Release: Positive Interim Safety Analysis Achieved in Breast Cancer Patients Treated With HER2/neu Antigens
1/9/2013 9:47:36 AM
More...
|
TapImmune Inc. (TPIV) Chairman Provides Corporate Update Including Progress on Clinical Trial Program and Scientific Collaborations
11/5/2012 9:27:43 AM
More...
|
TapImmune Inc. (TPIV) Release: Presentation of HER2/neu Vaccine Development Program at Third Annual Cancer Vaccines and Active Immunity Summit, Boston, June 27-29, 2012
6/26/2012 11:27:40 AM
More...
|
TapImmune Inc. (TPIV) to Present at NYC Medtech Forum on June 14, 2012
6/14/2012 10:18:51 AM
More...
|
TapImmune Inc. (TPIV) Announces the Appointment of James W. Fuller to the Board of Directors
5/18/2012 9:28:29 AM
More...
|
TapImmune Inc. (TPIV) Release: Phase I Clinical Trials on HER2/neu Antigens to Start at Mayo Clinic
5/4/2012 9:23:17 AM
More...
|
TapImmune Inc. (TPIV) Announces the Appointment of Mark Reddish to the Board of Directors
4/30/2012 9:49:51 AM
More...
|
|